Affiliation:
1. Ministry of Education, Wenzhou Medical University
2. Hangzhou Medical College
Abstract
Abstract
Nonalcoholic fatty liver disease (NAFLD) is associated with metabolic dysfunction, characterized by excess fat storage in the liver. Several studies have indicated that glutamine could be closely associated with lipid metabolism disturbances because of its important role in intermediary metabolism. However, the effect of glutamine supplementation on NAFLD progression remains unclear. Here, we used a high-fat diet (HFD)-induced NAFLD C57BL/6 mouse model, and glutamine was supplied in the drinking water at different time points for NAFLD prevention and reversal studies. A NAFLD prevention study was performed by feeding mice an HFD concomitant with glutamine treatment for 24 weeks, whereas the NAFLD reversal study was performed based on glutamine treatment for 13 weeks after feeding mice an HFD for 10 weeks. In the prevention study, glutamine treatment ameliorated serum lipid storage, hepatic lipid injury, and oxidative stress in HFD-induced obese mice, although glutamine supplementation did not affect body weight, glucose homeostasis, energy expenditure, and mitochondrial function. In the NAFLD reversal study, there were no noticeable changes in the basic physiological phenotype and hepatic lipid metabolism. In summary, glutamine might prevent, but not reverse, HFD-induced NAFLD in mice, suggesting that a cautious attitude is required regarding its use for NAFLD treatment.
Publisher
Research Square Platform LLC
Reference45 articles.
1. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases;Chalasani N;Hepatology,2018
2. Blond E, Disse E, Cuerq C, Drai J, Valette P-J, Laville M, Thivolet C, Simon C, Caussy C. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral? Diabetologia 2017, 60, (7), 1218–1222.
3. Brunt EM, Wong VWS, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E, Sirlin CB, Neuschwander-Tetri B, Rinella ME. Nonalcoholic fatty liver disease. Nature Reviews Disease Primers 2015, 1.
4. Mechanisms of NAFLD development and therapeutic strategies;Friedman SL;Nat Med,2018
5. Lean Indian patients with non-alcoholic fatty liver disease (NAFLD) have less metabolic risk factors but similar liver disease severity as non-lean patients with NAFLD;De A;Int J Obes (Lond),2023